Monitoring Circulating Tumor DNA in Patients With Early Stage Breast Cancer
Status: Recruiting
Location: See location...
Study Type: Observational
SUMMARY
This is a observational, single center study, monitoring the circulating tumor DNA (ctDNA) in patients with early breast cancer and assessing the prognostic value and treatment outcome monitoring of ctDNA.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 80
Healthy Volunteers: f
View:
• Patients aged 18 to 80 years old
• Histologically proven primary breast cancer with clinical stage I-III
• Patients with neoadjuvant therapy, and/or radical surgery/breast conserving surgery, adjuvant chemotherapy and target therapy (Her2+), radiotherapy (if indicated).
• Expected to achieve R0 resection.
• Estimated lifetime is more than 3 months.
• Signed Informed Consent Form
• Consent to provide research blood samples.
Locations
Other Locations
China
Army Medical Center of PLA, China
RECRUITING
Chongqing
Contact Information
Primary
Yan Xu, M.D.
xy931@163.com
(+86)159 2310 0038
Time Frame
Start Date: 2019-11-29
Estimated Completion Date: 2026-12
Participants
Target number of participants: 200
Related Therapeutic Areas
Sponsors
Leads: Geneplus-Beijing Co. Ltd.
Collaborators: Army Medical University, China